BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 112
- Registration Number
- NCT00160043
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 128
- Registration Number
- NCT00160069
Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2009-01-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT00119639
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 189
- Registration Number
- NCT00117637
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 101
- Registration Number
- NCT00110994
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2567
- Registration Number
- NCT00111020
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 270
- Registration Number
- NCT00111007
Research Study for Patients With Metastatic Renal Cell Carcinoma
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-05-09
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1
- Registration Number
- NCT00110344
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-04-22
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 96
- Registration Number
- NCT00108953
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-03-15
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 602
- Registration Number
- NCT00105443
© Copyright 2024. All Rights Reserved by MedPath